KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Cost of Revenue: 2017-2025

Historic Cost of Revenue for BeOne Medicines (ONC) over the last 8 years, with Sep 2025 value amounting to $196.5 million.

  • BeOne Medicines' Cost of Revenue rose 15.28% to $196.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $686.7 million, marking a year-over-year increase of 27.31%. This contributed to the annual value of $594.1 million for FY2024, which is 56.37% up from last year.
  • As of Q3 2025, BeOne Medicines' Cost of Revenue stood at $196.5 million, which was up 19.38% from $164.6 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Cost of Revenue registered a high of $196.5 million during Q3 2025, and its lowest value of $32.7 million during Q1 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $138.1 million (2024), whereas its average is $136.4 million.
  • Data for BeOne Medicines' Cost of Revenue shows a peak YoY surged of 153.46% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows BeOne Medicines' Cost of Revenue stood at $48.5 million in 2021, then spiked by 51.45% to $73.5 million in 2022, then skyrocketed by 43.95% to $105.8 million in 2023, then skyrocketed by 51.71% to $160.6 million in 2024, then climbed by 15.28% to $196.5 million in 2025.
  • Its Cost of Revenue was $196.5 million in Q3 2025, compared to $164.6 million in Q2 2025 and $165.0 million in Q1 2025.